# Ubiquinol in Parkinson's Disease: Safety, Tolerability, and Effects Upon Oxidative Damage and Mitochondrial Biomarkers

> **NCT03061513** · PHASE2 · COMPLETED · sponsor: **Weill Medical College of Cornell University** · enrollment: 11 (actual)

## Conditions studied

- Parkinson Disease

## Interventions

- **DRUG:** Ubiquinol
- **DIETARY_SUPPLEMENT:** Placebo

## Key facts

- **NCT ID:** NCT03061513
- **Lead sponsor:** Weill Medical College of Cornell University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-02-28
- **Primary completion:** 2016-12-31
- **Final completion:** 2016-12-31
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2017-05-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03061513

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03061513, "Ubiquinol in Parkinson's Disease: Safety, Tolerability, and Effects Upon Oxidative Damage and Mitochondrial Biomarkers". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03061513. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*